---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-086793"
form_type: "8-K"
ticker: "ATRA"
cik: "0001604464"
company_name: "Atara Biotherapeutics, Inc."
filed_at: "2026-03-03T23:59:59+00:00"
generated_at: "2026-05-15T22:15:56.509212+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Atara and Pierre Fabre request FDA Type A meeting for tabelecleucel BLA resubmission

## Summary
- Pierre Fabre submitted Type A meeting request to FDA to address CRL issues for tabelecleucel (EBVALLO) BLA.
- Briefing book argues ALLELE study was adequate; includes updated efficacy data and European post-marketing data.
- FDA Complete Response Letter was issued January 9, 2026; meeting seeks path forward for EBV+ PTLD therapy.
- CEO Cokey Nguyen cites urgent unmet need expressed by PTLD community and physician advocates.

## SEC filing metadata
- accession: 0001193125-26-086793
- form_type: 8-K
- ticker: ATRA
- cik: 0001604464
- company_name: Atara Biotherapeutics, Inc.
- filed_at: 2026-03-03T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000119312526086793/0001193125-26-086793-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000119312526086793/d121575d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-086793
- JSON: https://secwatch.observer/filing/0001193125-26-086793.json
- Plain text: https://secwatch.observer/filing/0001193125-26-086793.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.